Independent Research GmbH set a €76.00 ($90.48) price target on STADA Arzneimittel AG (ETR:SAZ) in a report released on Tuesday. The brokerage currently has a sell rating on the stock.

A number of other equities analysts also recently issued reports on the company. S&P Global set a €66.00 ($78.57) target price on STADA Arzneimittel AG and gave the stock a neutral rating in a research note on Monday, May 29th. Warburg Research set a €66.00 ($78.57) target price on STADA Arzneimittel AG and gave the stock a sell rating in a research note on Saturday, May 20th. Kepler Capital Markets set a €62.50 ($74.40) target price on STADA Arzneimittel AG and gave the stock a sell rating in a research note on Thursday, June 22nd. Finally, Commerzbank Ag set a €66.00 ($78.57) target price on STADA Arzneimittel AG and gave the stock a neutral rating in a research note on Tuesday, June 20th. Four equities research analysts have rated the stock with a sell rating and two have assigned a hold rating to the company. STADA Arzneimittel AG presently has an average rating of Sell and an average price target of €67.71 ($80.61).

Shares of STADA Arzneimittel AG (ETR SAZ) opened at 79.389 on Tuesday. The firm has a market capitalization of €4.94 billion and a price-to-earnings ratio of 52.471. STADA Arzneimittel AG has a one year low of €41.40 and a one year high of €84.20. The firm has a 50-day moving average price of €69.09 and a 200 day moving average price of €63.47.

ILLEGAL ACTIVITY NOTICE: “Independent Research GmbH Analysts Give STADA Arzneimittel AG (SAZ) a €76.00 Price Target” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/02/independent-research-gmbh-analysts-give-stada-arzneimittel-ag-saz-a-76-00-price-target.html.

About STADA Arzneimittel AG

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.

Analyst Recommendations for STADA Arzneimittel AG (ETR:SAZ)

Receive News & Stock Ratings for STADA Arzneimittel AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel AG and related stocks with our FREE daily email newsletter.